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Abstract 
We  report  our  institutional  experience  of
the management of 2 cases of rare non-Wilms’
tumors; a rhabdoid tumor in a 17-month old
boy and a clear cell sarcoma in a 5-year old
girl. The two patients were treated with ifos-
famide/carboplatin/etoposide  (ICE)  alternat-
ing  with  vincristine/doxorubicin/cyclophos-
phamide (VDC) and cyclophosphamide/etopo-
side (CE) alternating with vincristine/doxoru-
bicin/cyclophosphamide (VDC) and radiother-
apy,  respectively.  Both  patients  showed  full
response with no significant adverse events.
At  2-year  follow  up,  they  are  disease  and
relapse  free.  Although  contemporary  treat-
ment regimens are very promising, multicen-
ter collaborative studies are needed in order to
define  a  standard  treatment  for  non-Wilms’
tumors.
Introduction
Non-Wilms’ tumors comprise a rare and het-
erogeneous  group  of  renal  malignancies  in
children, including renal-cell carcinoma, clear-
cell sarcoma, (congenital) mesoblastic nephro-
ma, rhabdoid tumor, and renal medullary carci-
noma.1 Malignant rhabdoid tumor of the kid-
ney (MRTK) is a rare and aggressive pediatric
malignancy. It was first identified in 1978 as
an unfavorable histological subtype of Wilms’
tumor and was eventually distinguished as a
distinct  pathological  entity  in  1981.2 It
accounts  for  2%  of  childhood  renal  tumors
mostly  affecting  children,  predominantly
males, under the age of two years.3
Clear cell sarcoma of the kidney (CCSK) is
also considered a rare renal childhood malig-
nancy,  representing  about  3%  of  pediatric
renal tumors, and is associated with an unfa-
vorable  prognosis.4 It  predominantly  affects
males and shows a tendency for distant metas-
tasis, especially to bones.4 Treatment and prog-
nosis  of  non-Wilms’  tumors  in  infancy  and
childhood  are  considered  challenging  com-
pared  to  other  pediatric  malignancies.
Between January 1995 and December 2009, a
total of 14 renal tumors were managed in our
department.  Two  of  these  were  non-Wilms’
tumors. We report our institutional experience
on the management of these 2 cases, a rhab-
doid tumor in a 17-month old boy and a clear
cell sarcoma in a 5-year old girl, to provide fur-
ther information about these rare tumors.
Case Report #1
A 17-month old male infant presented with
vomiting and concurrent swollen scrotum. There
was no significant past medical or family history
and his growth and development had been nor-
mal. Abdominal ultrasonography demonstrated a
huge left-sided intrinsic renal mass. A subse-
quent  abdominal  computed  tomography  (CT)
scan confirmed the presence of a large mass
arising  from  the  left  kidney.  A  left  radical
nephrectomy was performed revealing a tumor
measuring  a  maximum  4.2  cm  in  diameter.
Gross examination showed a tumor which was
white in color with extensive necrosis, as well as
subcapsular fluid collection together with intra-
abdominal lymphadenopathy. 
Histological  examination  demonstrated
tumor cells with diffuse arrangement, contain-
ing  eccentric  nuclei  with  large  cherry-red
nucleoli  and  eosinophilic  cytoplasm  with
paranuclear  hyaline  inclusions  (Figure  1).
Immunohistochemical stains showed dot-like
cytoplasmic positivity for vimentin and epithe-
lial membrane antigen. There was no positivi-
ty for desmin, myogenin, cytokeratins cam5.2
and AE1/AE3, synaptophysin, protein S-100 and
antigen CD99. The findings were compatible
with malignant renal rhabdoid tumor. 
Intra-abdominal  lymph  nodes  were  tumor
free. Metastatic dissemination was not found
on subsequent imaging of the lungs and brain.
Initial tumor staging was grade II, based on the
NWTS-5  guidelines  and  the  patient  did  not
receive radiotherapy to the tumor bed. He did,
however, receive chemotherapeutic treatment
with  ifosfamide/carboplatin/etoposide  (ICE)
alternating with vincristine/doxorubicin/cyclo-
phosphamide (VDC). He showed full response
with no significant adverse effects. At 2-year
follow up, he remains disease and relapse free. 
Case Report #2
A 5-year old girl presented with a 6-week
history of microscopic hematuria that was ini-
tially  attributed  to  urinary  infection  and
received antibiotic treatment. There was no
significant past medical or family history and
her growth and development had been normal.
Due  to  the  persistence  of  hematuria,  an
abdominal  ultrasonography  was  performed
which revealed a large mass arising from the
left kidney which was confirmed by abdominal
CT. A left radical nephrectomy was performed
revealing a tumor measuring 10.5 cm in diam-
eter. The tumor mass was tan-grey in color,
composed  of  small  tumor  cells  with
eosinophilic cytoplasm and a mixture of cord
cells and septal cells with an extensive capil-
lary network. There were areas with pattern of
nests and cords, separated by spaced septe.
Immunohistochemical  staining  was  found
positive to vimentin and BCL2 and negative to
ceratins  CAM5.2  and  AE1/AE3,  EMA,  NSE,
synaptophysin, CD34, CD117, which is com-
patible with the diagnosis of a clear cell sarco-
ma of the kidney (Figure 2). Bone scan was
negative for bone metastases. The patient was
treated with a regimen of cyclophosphamide/
etoposide  alternating  with  vincristine/  dox-
orubicin/ cyclophosphamide according to the
ongoing COG AREN0321 with a minor modifi-
cation,  delivering  vincristine  and  cyclophos-
phamide with doxorubicin at week 0, rather
than  administering  doxorubicin  alone  and
delaying effective therapy. Radiotherapy at a
dose of 10.8Gy was administered at week 1.
The patient completed treatment without any
adverse events. During a 18-month follow-up
period the patient remains relapse and metas-
tases free.
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Discussion
Non-Wilms’ tumors represent a small propor-
tion of all childhood malignancies and are asso-
ciated with a poor prognosis. Rhabdoid tumors
were initially described as atypical and aggres-
sive variants of Wilms’ tumors in early child-
hood. They are currently regarded as a distinct
pathological entity that shares similar clinical
and radiological findings with Wilms’ tumors.
Therefore, histological examination is consid-
ered  mandatory  for  correct  diagnosis.2,5
Moreover, mutation of the hSNF5/INI gene on
chromosome  22,  considered  the  hallmark  of
MRT tumors, and the lack of staining of the INI1
gene  product,  can  help  to  confirm  diagnosis
with accuracy. In our cases, diagnosis of MRTK
was based on clinical symptoms, radiographic
findings  and  histopathology.  Hematuria  is  a
common presenting feature, but symptoms aris-
ing from metastases to distant organs are com-
mon  initial  findings  as  metastases  occur  in
about 80% of patients, most frequently in lungs
and  brain.1,6 Hypercalcemia  has  also  been
reported  in  infants  with  MRTK.7,8 Computed
tomography imaging of lungs and brain is rec-
ommended as part of the initial evaluation for
all children with RTK. More recently, molecular
genetics have revealed a mutation of the SMAR-
CB1/hSNF5/INI1 gene which can help confirm
diagnosis.8
Non-Wilms’ tumors are associated with the
worst prognosis among all neoplasms involv-
ing the kidney in early life. Age is an important
prognostic factor, and patients under the age of
two years have the worst prognosis.9 Low stage
and the extent of radical surgical excision are
also important determinants for long-term sur-
vival.  Historically,  patients  with  MRTK  were
treated  with  National  Wilms  Tumour  Study
Group  (NWTSG)  protocols  comprising  vin-
cristine, actinomycin and doxorubicin, with or
without  cyclophosphamide.4,10 Unfortunately,
reported outcomes from both the NWTSG and
SIOP (Society of Pediatric Oncology) protocols
are poor. Recent reports have shown encourag-
ing results with a combination of ifosfamide/
carboplatin/etoposide  (ICE)  alternating  with
vincristine/doxorubicin/cyclophosphamide
(VDCy).11,12 We  followed  this  protocol  and
observed a full response and a 2-year period of
disease free survival.
Clear Cell Sarcoma of the Kidney (CCSK)
represents another rare renal childhood malig-
nancy. It is a distinct clinico-pathological entity
from Wilms’ tumor. It is more commonly found
in males with a peak incidence at 1-4 years of
age, usually presenting as an abdominal mass.
It  shows  a  propensity  to  metastasize  to  the
bones.4 Addition of doxorubicin to vincristine
and actinomycin has shown a beneficial effect
on survival according to NWTS1,2,3.4 NWTS-3
revealed  no  improvement  in  outcome  when
cyclophosphamide was added to a combination
of  vincristine,  dactinomycin  and  doxorubicin
but it is to be argued that cyclophosphamide
was delivered at a relatively low dose and inten-
sity. In NWTS-5 (now the Children’s Oncology
Group, COG), patients with CCSK are treated
with a protocol consisting of vincristine/dox-
orubicin/cyclofosfamide  (VDC)  alternating
with  cyclofosfamide/etoposide  (CE).13,14 Our
patient (Case Report 2) was treated according
to that treatment regimen following nephrecto-
my combined with postoperative radiotherapy.
Treatment  outcome  was  excellent  with  the
patient  in  remission  at  18-month  follow  up.
Nevertheless, metastatic progression or relapse
remains a main concern in this patient.
Multicenter collaborative studies are required
in order to create a standard for the manage-
ment of non-Wilms’ tumors, as well as to assess
the safety and efficacy of new treatment regi-
mens. In addition, long-term toxicity, together
with the cost and psychological burden for the
patients and their families need to be addressed
in  modern  multimodal  intensive  therapies  of
patients with advance stage disease.
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Case Report
Figure  1. Typical  histological  features  of
malignant  renal  rhabdoid  tumor
(Haematoxylin & Eosin x400).
Figure 2. Clear spaces between tumor cells
and empty nuclei (Haematoxylin & Eosin
x400).